Irritable bowel syndrome symptom severity improves equally with probiotic and placebo by Lyra, Anna et al.
Anna Lyra, Julia Tennilä, Anneli Tarpila, Sampo Lahtinen, 
Arthur C Ouwehand, DuPont Nutrition and Health, Global 
Health and Nutrition Science, Danisco Sweeteners Oy, 02460 
Kantvik, Finland
Markku Hillilä, Clinic of Gastroenterology, University of 
Helsinki and University Hospital, 00290 Helsinki, Finland
Teppo Huttunen, Sofia Männikkö, Mikko Taalikka, 4Pharma 
Ltd, Lemminkäisenkatu 1, 20520 Turku, Finland
Lea Veijola, Mehiläinen Oy, Pohjoinen Hesperiankatu 17, 00260 
Helsinki, Finland
Author contributions: Lyra A, Hillilä M, Huttunen T, Männikkö 
S, Taalikka M, Tennilä J, Tarpila A, Lahtinen S, Ouwehand AC 
and Veijola L designed the study; Veijola L was the principal 
investigator and Hillilä M was the co-investigator; Lyra A and 
Ouwehand AC managed the trial; Huttunen T and Männikkö S 
were responsible for the statistics; Taalikka M performed the data 
management; Tennilä J and Tarpila A monitored the trial; Lyra 
A, Hillilä M, Huttunen T, Männikkö S, Taalikka M, Tennilä J, 
Ouwehand AC, and Veijola L wrote the manuscript; all authors 
have read and approved the manuscript.
Institutional review board statement: This study was 
reviewed and approved by the Hospital District of Helsinki 
and Uusimaa (HUS) Ethics Committee of Medicine (initial 
ethical approval 251/13/03/01/2012 dated 15.8.2012, received 
17.8.2012).
Clinical trial registration statement: This study has been 
registered at Clinicaltrials.gov. The registration identification 
number is NCT01728610. The study was registered before study 
recruitment commenced.
Informed consent statement: All volunteers provided written 
informed consent before any study-specific procedures or 
assessments were performed.
Conflict-of-interest statement: Anna Lyra, Julia Tennilä, 
Anneli Tarpila, Sampo Lahtinen, and Arthur C Ouwehand are 
present or former employees of the sponsor, DuPont Nutrition 
and Health.
Data sharing statement: No additional data are available. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Unsolicited manuscript 
Correspondence to: Anna Lyra, PhD, Senior Scientist, 
DuPont Nutrition and Health, Global Health and Nutrition 
Science, Danisco Sweeteners Oy, Sokeritehtaantie 20, 02460 
Kantvik, Finland. anna.lyra@dupont.com
Telephone: +358-40-8241732
Fax: +358-10-4315555
Received: April 13, 2016
Peer-review started: April 14, 2016
First decision: June 20, 2016
Revised: July 13, 2016
Accepted: July 31, 2016
Article in press: August 1, 2016
Published online: December 28, 2016
Abstract
AIM
To determine the effects of Lactobacillus acidophilus 
NCFM on irritable bowel syndrome (IBS) symptoms and 
quality of life (QoL).
METHODS
In this randomized triple-blind trial, adult IBS volunteers 
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who were recruited according to Rome Ⅲ criteria 
received 109 or 1010 colony-forming units of NCFM or 
placebo daily for 12 wk. IBS Symptom Severity Score 
(IBS-SSS), which constituted the primary outcome, 
and secondary outcomes, including individual IBS 
symptoms, IBS-related QoL questionnaire, anxiety and 
depression, defecation frequency, and stool consistency, 
were assessed at baseline at the end of the 8-wk run-
in period, after 4 and 12 wk of intervention, and after a 
4-wk washout.
RESULTS
A total of 340 of 391 randomized volunteers completed 
the trial. IBS-SSS improved over 12 wk of treatment 
in all treatment groups, decreasing by a mean ± 
SD of 44.0 ± 80.2, 50.8 ± 82.4, and 48.3 ± 72.2 in 
the placebo, active low-dose, and active high-dose 
groups, respectively. Similarly, secondary outcomes 
did not differ between treatment groups. However, 
in a post hoc analysis of volunteers with moderate to 
severe abdominal pain at baseline (VAS > 35/100), 
the treatment significantly reduced the sensation of 
abdominal pain. Pain scores fell by 20.8 ± 22.8, 29.4 ± 
17.9, and 31.2 ± 21.9 in the placebo, active low-dose, 
and active high-dose groups, respectively (P  value for 
placebo vs  combined active doses = 0.0460).
CONCLUSION
NCFM alleviates moderate to severe abdominal pain, 
consistent with earlier observations of this strain 
mitigating visceral pain through increased analgesic 
receptor expression.
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Core tip: Symptoms of irritable bowel syndrome (IBS) 
might benefit from probiotic interventions, although 
mechanistic insights into probiotic function are seldom 
available. Lactobacillus acidophilus  NCFM induces 
human colonic mucosal opioid receptor expression - the 
putative mechanism by which visceral pain is alleviated. 
In this study, 391 volunteers with IBS were treated 
with 109 or 1010 colony-forming units of NCFM or 
placebo and evaluated using symptom questionnaires. 
NCFM was not superior to placebo in improving the 
composite IBS symptom score, whereas abdominal pain 
- as an individual symptom - declined in IBS volunteers 
with moderate to severe pain at baseline.
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INTRODUCTION
With a prevalence of 5% to 16% in northern Europe, 
irritable bowel syndrome (IBS) imposes considerable 
health care costs on society[1,2]. IBS affects adult 
age groups evenly but is more common in women[2]. 
According to the European Food Safety Authority, IBS 
volunteers can be recruited as an appropriate group 
for studying bowel discomfort symptoms that also 
affect the general population[3], allowing the results to 
be extrapolated to a wider potential market. 
A host’s gastrointestinal (GI) microbiota can 
contribute to IBS etiology and symptomology through 
changes in bacterial abundance and fermentation 
products, lower diversity, and instability over time, 
which are associated with increased epithelial 
permeability, aberrations in immunity and brain-gut 
interactions, and altered GI neuromuscular function[4-7]. 
Thus, manipulation of the GI microbiota with probiotics 
is a putative therapeutic option for IBS [4,8]. 
Probiotics, defined as “live microorganisms that, 
when administered in adequate amounts, confer a 
health benefit on the host”[9], have shown efficacy 
in selected randomized clinical trials in relieving IBS 
symptoms and are generally well tolerated[10-12]. 
However, the quality of several probiotic intervention 
studies has been limited due to inadequate sample 
sizes and intervention periods, poor trial design, and 
undefined or unstable probiotic products[13]. Moreover, 
each strain or combination of strains and each dose 
requires a separate clinical trial to show efficacy [9,10].
Our aim was to perform a high-quality, randomized, 
triple-blind, and placebo-controlled dose-response 
clinical trial of 3 statistically adequately sized parallel 
groups. The supplement that we examined is a well-
characterized and stable probiotic strain, mechanistic 
studies of which have reported putative efficacy in 
alleviating visceral pain. Lactobacillus acidophilus NCFM 
increases the visceral pain threshold in a rat model by 
44% through the opioid pathway[14] and upregulates 
μ-opioid receptor (MOR) in humans[15]. 
Participant-reported severity of functional bowel 
symptoms, however, has merely been evaluated for 
a high-concentration combination of L. acidophilus 
NCFM and Bifidobacterium animalis subsp. lactis 
Bi-07[16], which is significantly less effective in increasing 
MOR expression than L. acidophilus NCFM alone[15]. 
Therefore, assessment of the clinical effects of L. 
acidophilus NCFM as a single-strain supplement for 
functional bowel symptoms, including visceral pain, 
was essential. Two doses, 109 and 1010 colony-forming 
units (CFU), were selected as clinically adequate and 
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applicable for use in consumer products.
MATERIALS AND METHODS
Study volunteers
This trial was performed at 2 private clinics in Helsinki 
and Turku, Finland, from October 2012 to November 
2014. Newspaper and radio advertisements, followed 
by prescreening phone calls, were used to invite 
potential eligible volunteers to screening visits that 
were held by gastroenterologists who were experienced 
in functional bowel disorders, including IBS. The re-
cruited volunteers were adults (18-65 years) who were 
diagnosed with IBS according to Rome Ⅲ criteria[17]. 
Volunteers who suffered from severe IBS symptoms 
were excluded due to the use of medications (strong 
pain medication, diarrhea medication, and laxatives) 
that might have confounded the primary outcome 
measure. Other inclusion criteria were sufficient general 
health and orientation for participation in the study, 
adequate Finnish language skills for being interviewed 
and completing questionnaires, high likelihood of 
compliance with and completion of the study, and a 
body mass index (BMI) between 19 and 35. 
Volunteers were excluded if they had participated 
in a clinical trial with an investigational product (IP) or 
drug within 3 mo prior to the screening, were likely 
to be noncompliant with the protocol or judged to be 
unsuitable for study participation by the investigator 
for any reason, were planning major changes in 
lifestyle (e.g., diet, dieting, exercise level, travel), had 
a history of drug or alcohol abuse, were pregnant or 
breastfeeding, were diagnosed with or suspected of 
having organic GI disease (e.g., colitis, Crohn’s disease, 
celiac disease, bowel surgery, recurrent diverticulitis), or 
had severely impaired general health, including cancer 
and cancer therapy. Lactose-intolerant volunteers were 
allowed to enter the trial if they followed a non lactose 
diet. Any previous allergic reaction to any substance 
in the study product was also considered an exclusion 
criterion. 
Medications that could affect the outcomes, including 
anticholinergic medications, antibiotics (including 
use during the 3 mo prior to the start of the study), 
pain medications that contained opiates or morphine, 
weight loss medication, misoprostol, 5-HT3 receptor 
antagonists, antacids with magnesium or aluminum, 
diarrhea medication, medication that accelerates the 
emptying of the stomach, sulfasalazine, laxatives, 
cholestyramine, cytostatics, biological medications, 
oral steroids (3 mo prior to and during the study), and 
probiotic products, excluded subjects from participation 
in the trial. Iron supplements, antidepressants, fiber 
supplements, statins, thyroxine, coxibs, acid medication, 
inhaled steroids, and other non excluding medications 
that did not affect outcome measures in the clinician’
s opinion were allowed during the trial if they had been 
consumed for at least 30 d at the same dose.
During the screening visit, thorough demographic 
data were collected, including lifestyle habits, diet, 
medical history, and family history of GI disturbances. 
Screening safety blood tests included a basic blood 
count, C-reactive protein (CRP), celiac test, lactase 
gene test, and thyroid-stimulating hormone for con-
stipated IBS volunteers. The test results complied with 
the inclusion and exclusion criteria and were clinically 
within normal-range values according to the recruiting 
gastroenterologists.
Study design
The trial was a randomized, triple-blind (volunteers, 
investigators, and statisticians blinded), placebo-
controlled, dose-response intervention to determine 
the efficacy of a probiotic supplement in reducing 
IBS Symptom Severity Score (IBS-SSS)[18]. The trial 
comprised an 8-wk run-in period, a 12-wk intervention 
phase, and a 4-wk washout period (Figure 1). Outcome 
measures were assessed using questionnaires, and 
adverse events (AEs) were recorded through phone 
calls. Volunteers who withdrew were not replaced.
The primary outcome was the change in IBS-SSS 
from baseline at the end of the run-in period to after 
12 wk of treatment[18]. IBS-SSS is a composite score of 
abdominal pain, number of days with abdominal pain, 
bloating/distension, satisfaction with bowel habits, 
and IBS-related quality of life (QoL). Each measure is 
rated from 0 to 100, with total scores ranging from 0 
to 500. Based on previous trials[19,20], a 15% change in 
the IBS-SSS was determined to be clinically significant 
in measuring efficacy. QoL was evaluated with a 
thorough 34-item IBS-related QoL questionnaire (IBS-
QoL), analyzed as a total score and as subscales on 
dysphoria, interference with activity, body image, 
health-related worries, food avoidance, social rea-
ctions, sexuality, and relationships[21]. Psychological 
comorbidities were evaluated with the Hospital Anxiety 
and Depression Scale (HADS) questionnaire[22].
IBS-SSS, IBS-QoL, and HADS data were collected 
at the end of the run-in, after 4 and 12 wk of treatment, 
and after the 4-wk washout. Weekly bowel movement 
frequency and consistency were recorded prior to 
each outcome assessment time point with an in-
house questionnaire, based on the Bristol Stool Form 
Scale[23]. For analysis, stool consistencies were grouped 
into constipation (Bristol Scale 1 or 2), diarrhea (Bristol 
Scale 6 or 7), and normal (Bristol Scale 3, 4, or 5). 
Overall satisfaction with the treatment with regard 
to IBS symptoms was measured with a dichotomous 
adequate relief (AR) question[24]. The volunteers 
were instructed to compare AR from IBS symptoms 
during the past week to their symptom severity prior 
to consuming IPs. Volunteers who reported AR for at 
least half of the intervention weeks were considered to 
be responders. AR data were collected throughout the 
12-wk intervention.
Prior to each visit (end of run-in, week 4, week 12, 
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registered at Clinicaltrials.gov under the identifier 
NCT01728610.
Data quality assurance
Case report forms were 100% monitored and double-
entered independently into a database that was 
created with SAS®. Queries were raised in cases of 
illegible, missing, or inconsistent data. All discrepancies 
were resolved before the database was locked. 
Data management and statistics were performed by 
4Pharma Ltd.
Statistical analyses
Determination of sample size: The primary analysis 
variable was the change in IBS-SSS from baseline 
to week 12. Baseline levels were estimated to be 
approximately 250 (halfway on the 0-500 scale). 
A difference of 15% - i.e., 37.5 points - was used 
in the sample size calculation[20]. Using 80% power 
and a 2-sided alpha level of 0.05, the sample size 
was calculated to be 104 for each group. Taking into 
account a discontinuation rate of 20%, approximately 
390 patients were needed for randomization. The 
sample sizes were calculated using NQuery Advisor, 
version 7.0.
Analysis sets: The intent-to-treat dataset (ITT) 
included all randomized volunteers who received at 
least 1 dose of the IP and had at least 1 post baseline 
efficacy measurement available. The per protocol 
dataset (PP) was a subset of the ITT dataset, excluding 
volunteers and measurements for a given volunteer 
with major protocol violation(s) or concomitant 
medication use that was expected to alter the primary 
outcome. Volunteer classification into the ITT and PP 
populations was detailed after locking the database 
and completed before the study was unmasked. In 
addition, post hoc analyses of volunteers with IBS-SSS 
pain score VAS > 35/100 were performed.
and end of washout), research nurses contacted the 
volunteers by phone to inquire about AEs and remind 
them of the sampling time point procedures.
Study treatment
The IPs were administered orally in 1 daily capsule that 
contained 109 (low dose) or 1010 (high dose) CFU of L. 
acidophilus NCFM (ATCC 700396), with microcrystalline 
cellulose as the excipient or microcrystalline cellulose 
as placebo. All treatments were supplied by Danisco 
USA (Madison, Wisconsin, United States). The formu-
lations of all 3 treatments were similar in smell, taste, 
and appearance. The IPs were stored at -20 ℃ until 
they were distributed to the clinics, where they were 
refrigerated below 6 ℃. Volunteers were allowed to 
store the IPs refrigerated or at room temperature. The 
CFU counts were checked in the active and placebo 
products during and after the trial.
Laboratory measures
Screening safety tests were performed by certified 
clinical laboratories of the private clinics Mehiläinen 
Töölö (Helsinki, Finland) and Mehiläinen Turku (Turku, 
Finland).
Compliance testing
Volunteers received 84 capsules and were instructed 
to return the container after the 84-d treatment 
period. Leftover capsules were counted to estimate 
compliance.
Ethical considerations
This study was conducted according to the 2008 
Sixth Revision of the Declaration of Helsinki, the EMA 
Note for Guidance on Good Clinical Practice (CPMP/
ICH/135/95 - in operation 17.01.97), and laws and 
regulations for clinical research in Finland. Written 
informed consent was obtained from each volunteer 
before any study-specific procedures. The trial was 
Figure 1  Study outline. Volunteers were selected for screening visits by a prescreen for compliance over the phone. Eligible volunteers entered an 8-wk run-in 
period without any investigational product (IP) consumption and were thereafter randomized to receive low- or high-dose active IP or a placebo IP for 12 wk. The 
intervention period was followed by a 4-wk washout period without any IP consumption. Preceding each time point (weeks 0, 4, 12, and 16), volunteers recorded their 
stool consistency during each defecation event for 7 d. At each time point, questionnaires [Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS); IBS-related 
Quality of Life (IBS-QoL); Hospital Anxiety and Depression Score (HADS)] were filled out. All volunteers were contacted by phone prior to each sampling time point to 
inquire about adverse events (AEs) and to remind of the sampling procedures.
Pre-screening and screening
Base-line measurements and randomization
Phone contact to enquire AEs and to remind of questionnaires to be answered
Begin of 7-d defecation frequency and stool consistency data collection 
IBS-SSS, IBS-QoL and HADS questionnaires filled
End of defecation frequency and stool consistency data collection
-8 0 4 16
Run in 8 wk
Week
Intervention 12 wk
12
Wash-out 4 wk
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Randomization: Volunteers were randomized at 
the end of the 8-wk run-in phase, because the long 
run-in period created risk of a high dropout rate. 
Randomization was performed with Research Ran-
domizer[25], applying non repeating numbers in blocks 
of 6. Volunteers, investigators, statisticians, and 
monitors were blinded until the database was locked 
and the Statistical Analyses Plan was completed. The 
clinics were supplied with sealed, volunteer-specific 
envelopes for revealing the randomization code, if 
required by the investigators. None of the envelopes 
was opened during the trial.
Analysis of efficacy: Descriptive statistics for all 
variables were computed, and the disposition of 
volunteers was summarized by treatment. The primary 
efficacy variable (change in IBS-SSS from baseline) 
was analyzed using a repeated measures analysis of 
covariance (RM ANCOVA) model. The differences (low 
dose vs placebo and high dose vs placebo) in changes 
from baseline in IBS symptom score at 12 wk and their 
95%CI were estimated with the RM ANCOVA model. 
Explorative comparisons were performed for high dose 
vs low dose and combined active group vs placebo and 
for within-group changes from baseline. 
The individual domains of the IBS-SSS were 
analyzed with a similar RM ANCOVA model that was 
applied for IBS-SSSs. A logistic regression model was 
used to compare treatment groups against placebo 
for AR responder status. Changes in HADS and IBS-
QOL scores from baseline were analyzed using an RM 
ANCOVA model. The stool consistencies (Bristol Stool 
Form) and defecation frequencies were summarized 
descriptively. Simple t-test was used in the post 
hoc analyses of subgroups (e.g., pain score VAS > 
35/100).
All statistical analyses and volunteer data listings 
were performed at 4Pharma Ltd using SAS, version 9.3 
(SAS Institute Inc., Cary, NC, United States).
Safety analyses: All randomized volunteers who 
received the study treatment were included in the 
safety analysis. AEs were counted by volunteer, event, 
type, treatment, severity, and causality. Each symptom 
of an AE or serious adverse event (SAE) case was 
recorded separately.
The statistical methods were reviewed by statistician 
Teppo Huttunen, 4Pharma Ltd.
RESULTS
Altogether, 618 volunteers were prescreened by 
telephone interview for compliance with the inclusion 
and exclusion criteria, and thereafter, the eligibility 
of 529 potential volunteers was confirmed by gastro-
enterologists. A total of 471 volunteers entered the 
trial, of whom 391 were randomized after the 8-wk run-
in phase, with 340 (87%) completing the trial (Figure 2). 
The results are presented for the ITT dataset; those for 
the PP dataset were comparable.
Demographics and baseline characteristics
The volunteers from Helsinki (n = 276; 34 dropouts) 
and Turku (n = 115; 17 dropouts) were randomized 
evenly to the 3 treatments. The treatment groups 
were comparable with regards to age, sex, BMI, and 
lifestyle habits, including type of diet, exercise level, 
alcohol consumption, smoking (Table 1), and IBS 
symptom characteristics (Table 2). All groups were 
predominantly female (71.8% to 79.4% female), and 
men had a higher BMI (60.6% and 36.6% of male 
and female volunteers, respectively, had a BMI > 25). 
All findings on vital signs and the safety blood tests 
taken at screening were evaluated for their clinical 
significance in relation to the inclusion and exclusion 
criteria.
Prior and concomitant medications 
Prior and concomitant medications for the alimentary 
tract, pain, and anxiety/depression were recorded, 
with gastroenterologists evaluating any putative bias 
of them on efficacy measures. The most common 
medications used before and during the study were 
drugs for gastric acid disorders, nonsteroidal anti-
inflammatory drugs, and antidepressants/anxiolytics. 
Also, 36 volunteers were on thyroxine medication due 
to hypothyreosis.
IP quality check and compliance
The L. acidophilus NCFM CFU count was confirmed 
to be adequate for both active treatment doses (> 
1.04 × 1010 and > 9.8 × 109 CFU/capsule for the high 
and low doses, respectively). For the placebo, the L. 
acidophilus NCFM count was below < 3.2 × 102 CFU/
capsule. According to the number of returned capsules 
95%, 95%, and 94% of IP capsules were consumed 
in the placebo and low-dose and high-dose treatment 
groups, respectively.
Efficacy 
The IBS-SSS improved significantly from baseline to 
the end of the intervention by a mean ± SD of 44.0 
± 80.2, 50.8 ± 82.4, and 48.3 ± 72.2 in the placebo, 
low-dose, and high-dose groups, respectively (P < 
0.001 for all groups), with no significance between 
the placebo and active groups (Figure 3). Results 
for individual IBS-SSS item scores were comparable 
between groups (Table 3). However, in a post hoc 
analysis of a subgroup of volunteers who suffered 
from moderate to severe pain (pain score VAS > 
35/100 at baseline), L. acidophilus NCFM significantly 
reduced abdominal pain in the combined active groups 
compared with placebo (Table 4).
During the intervention period, 28.4%, 25.0%, and 
26.5% of volunteers considered their IBS symptoms 
to have been adequately relieved with the placebo, 
Lyra A et al . Probiotic intervention on IBS symptoms
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Table 1  Baseline demographics mean ± SD or n  (%)
Characteristics Placebo (n  = 131) Low-dose (n  = 129) High-dose (n  = 131)
Age (yr)   49.4 ± 12.9   47.1 ± 13.3   47.2 ± 12.5
Gender
   Male 37 (28.2) 35 (27.1) 27 (20.6)
   Female 94 (71.8) 94 (72.9) 104 (79.4)
BMI (kg/m2) 24.9 ± 3.7 24.7 ± 3.7 24.5 ± 3.9
Diet
   Low-carbohydrate 2 (1.5) 0 (0.0) 0 (0.0)
   Vegetarian 1 (0.8) 2 (1.6) 0 (0.0)
   Non-lactose 26 (19.8) 32 (24.8) 26 (19.8)
   Regular 77 (58.8) 63 (48.8) 67 (51.1)
Probiotics
   Daily user 24 (18.3) 25 (19.4) 18 (13.7)
   Irregular user 18 (13.7) 17 (13.2) 29 (22.1)
   History of using 65 (49.6) 62 (48.1) 66 (50.4)
   No use 23 (17.6) 25 (19.4) 18 (13.7)
   N/A 1 (0.8) 0 (0.0) 0 (0.0)
Exercise level
   > 30 min 3 times a week 62 (47.3) 63 (48.8) 59 (45.0)
   ≤ 30 min 3 times a week 57 (43.5) 56 (43.4) 63 (48.1)
   No exercise 12 (9.2) 10 (7.8) 9 (6.9)
Alcohol consumption
   > 14 units/wk 1 (0.8) 0 (0.0) 0 (0.0)
   ≤ 14 units/wk 96 (73.3) 90 (69.8) 90 (68.7)
   Non-drinker 34 (26.0) 39 (30.2) 41 (31.3)
Tobacco smoking
   Current use 11 (8.4) 11 (8.5) 14 (10.7)
   Never used 80 (61.1) 86 (66.7) 88 (67.2)
   History of use 40 (30.5) 32 (24.8) 29 (22.1)
Drug abuse
   Never used 131 (100) 129 (100) 131 (100)
Figure 2  Disposition of volunteers. During the 8-wk run-in period prior to randomization, 17% of eligible volunteers dropped out. After randomization, most 
volunteers (87%) completed the trial. Withdrawals were evenly distributed between treatment groups. Low- and high-dose treatment groups received 109 or 1010 CFU 
Lactobacillus acidophilus NCFM daily.
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low-dose, and high-dose treatments, respectively 
(P = 0.8371 between groups by logistic regression). 
The IBS-QoL reflected a higher QoL at the end of the 
intervention in all treatment groups (Table 5), although 
neither active treatment dose was superior to placebo. 
The HADS total score declined significantly from 
baseline to the end of the intervention in both active 
treatment groups, HADS anxiety improved significantly 
in all treatment groups, but HADS depression improved 
significantly only in the high-dose group. However, none 
of the between-group comparisons reached statistical 
significance, although total HADS and HADS anxiety 
were slightly lower in the high-dose group compared 
with placebo (Table 5).
None of the treatments had undesired effects on 
stool consistency (Table 6).
Safety results
AEs were evenly distributed in all groups, with 81, 57, 
and 61 AEs recorded during the treatment period in the 
placebo, low-dose, and high-dose treatment groups, 
respectively. The most common treatment-emergent 
AEs were GI disorders (abdominal discomfort, ab-
dominal distension, abdominal pain, constipation, 
diarrhea, flatulence), gastroenteritis, and influenza. 
Potentially IP-related AEs - mild GI symptoms, which 
might also have been due to all volunteers having IBS 
that presented with similar symptoms - were recorded 
for 7, 7, and 9 volunteers in the placebo, low-dose, 
and high-dose treatment groups, respectively. 
AEs led to discontinuation 10, 4, and 3 times in 
the high-dose, low-dose, and placebo groups, re-
spectively, but these cases were not considered IP-
related safety issues, based on the possibility of the 
IP-related cases being general IBS symptoms. Two 
SAE cases that presented with 3 symptoms were 
encountered: pneumonia with fever and cough and a 
case of syncope that resulted in a hospital visit; neither 
was associated with the IP or any trial procedure. The 
case of pneumonia, which involved hospitalization and 
antibiotic treatment, led to discontinuation. 
DISCUSSION
This study is the first adequately powered clinical 
trial to determine the effects of L. acidophilus NCFM 
on IBS symptoms using patient-reported outcomes. 
The L. acidophilus NCFM strain is well characterized[26] 
and has been commercially available as a probiotic 
for several decades. It has been associated with the 
alleviation of the perception of visceral pain as a 
2-strain blend with B. lactis Bi-07 in volunteers with 
bloating and among colonoscopy patients[14,15,27]. In a 
mechanistic study, however, L. acidophilus NCFM, as 
a single-strain supplement, was more effective than 
the combination in enhancing human colonic MOR 
expression and activity, although both treatments 
relieved bowel symptoms, albeit insignificantly[15,16].
L. acidophilus NCFM has been shown to elevate 
the visceral pain threshold in a rat model by 44% 
Table 2  Irritable bowel syndrome symptom characteristics n  (%)
Placebo (n  = 131) Low-dose (n  = 129) High-dose (n  = 131)
IBS subtype
   IBS-C 25 (19.1) 20 (15.5) 20 (15.3)
   IBS-D 49 (37.4) 51 (39.5) 52 (39.7)
   IBS-M 56 (42.7) 58 (45.0) 58 (44.3)
   IBS-U 1 (0.8) 0 (0.0) 1 (0.8)
Postinfectious IBS 9 (6.9) 4 (3.1) 7 (5.3)
Psychological comorbidities 9 (6.9) 6 (4.7) 13 (9.9)
Symptoms provoked by specific food 103 (79.8)1 116 (89.9) 120 (91.6)
Family history of intestinal disorders or diseases 95 (72.5) 97 (75.2) 92 (70.8)2
1Two volunteers not analysed; 2One volunteer not analyzed. IBS: Irritable bowel syndrome.
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Figure 3  Irritable bowel syndrome symptom severity score over time. IBS-
SSS is a 5-item composite score inquiring about the severity of abdominal pain, 
bloating/distension, satisfaction with bowel habits, and IBS-related quality of life 
on a 10-cm VAS scale and the number of days with abdominal pain over the 
past 10 d[18]. All items are scored from 0 to 100, allowing for IBS-SSSs to range 
from 0 to 500. Francis and colleagues have validated non-IBS controls and 
volunteers suffering from mild, moderate, and severe IBS symptoms to range 
between 0-75, 75-175, 175-300, and 300-500, respectively[18]. The composite 
symptom score declined similarly in all treatment groups during the intervention, 
showing no treatment effect for the active groups (low-dose and high-dose) 
receiving Lactobacillus acidophilus NCFM. The severity scores are given as 
mean ± SD. Differences from baseline to week 12 were not significant between 
treatment groups. All within-group comparisons to baseline (week 4, week 12, 
and washout) were significant (P < 0.001). IBS-SSS: Irritable bowel syndrome 
symptom severity score; IBS: Irritable bowel syndrome.
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through the MOR-mediated pathway with an efficacy 
that is comparable with that of 1 mg/kg subcutaneous 
morphine[14]. Thus, there was tremendous interest in 
determining the efficacy of L. acidophilus NCFM as a 
single-strain supplement in mitigating functional bowel 
symptoms.
The volunteer recruitment was successful, and the 
trial completion rate and IP compliance were high. 
All 391 randomized volunteers fulfilled the Rome 
Ⅲ criteria for IBS, with an even distribution of IBS 
subtypes and demographics between groups. Blood 
tests were performed at the screening visit (basic 
blood count and CRP) to rule out inflammatory causes 
of the bowel symptoms. Most volunteers (57%) had 
undergone a colonoscopy in the past due to chronic 
GI symptoms to rule out organic or inflammatory 
causes, but endoscopy was not performed during the 
screening. 
Based on a crossover trial that raised concerns 
over the inadequate length of a 1-mo run-in period[28], 
all volunteers refrained from using any commercial 
or trial-related probiotics over an 8-wk run-in period 
to reduce any putative carryover effects. A total 
of 83% of randomized volunteers had a history of 
consuming commercial probiotics. The intervention 
period was designed to last for 12 wk to follow up on 
the efficacy and AEs for a sufficient period of time[10] 
and to limit the placebo effect toward the end of the 
trial. Altogether, we recruited an adequate number of 
reliably diagnosed, extensively examined volunteers 
who were not using any concomitant medications or 
supplements that could have affected outcomes. The 
treatment was a well-characterized probiotic strain 
that was supplemented in 2 common doses for an 
adequately long intervention period.
However, in this trial, based on a composite score of 
IBS symptom severity (IBS-SSS), L. acidophilus NCFM 
was not superior to placebo. No significant differences 
in the secondary outcomes were observed between 
groups, and none of the outcomes showed a dose-
response effect. Nevertheless, in post hoc analyses of 
a subgroup that presented with moderate to severe 
abdominal pain at baseline (IBS-SSS pain score on 
VAS > 35/100 at baseline; active groups combined vs 
placebo), the level of abdominal pain declined in the 
active groups at week 12. These data are consistent 
with previous mechanistic findings of greater MOR 
expression and activity during L. acidophilus NCFM 
treatment in humans and rats[14,15] and earlier recovery 
from colonoscopy-associated pain[27]. 
Table 3  Irritable bowel syndrome symptom severity score item scores at baseline and end of intervention
Treatment Baseline Week 12 Change from 
baseline
Within-group 
comparison
Comparison with 
placebo
Comparison with 
low- and high-dose
n mean ± SD n mean ± SD mean ± SD P value P  value P  value
Severity of pain
   Placebo 121 20.2 ± 20.6 118 18.5 ± 20.7   -2.2 ± 21.8    0.024 NA 0.303
   Low-dose 124 24.1 ± 22.3 110 18.3 ± 18.6   -5.2 ± 24.4    0.005 0.640 NA
   High-dose 122 24.3 ± 21.5 113 16.4 ± 17.8   -7.9 ± 21.8 < 0.001 0.189 NA
Number of days with pain over 10 d
   Placebo 114 3.8 ± 2.8 111 2.8 ± 2.8 -1.0 ± 2.7 < 0.001 NA 0.234
   Low-dose 115 4.4 ± 2.8 105 3.3 ± 2.6 -1.1 ± 2.9 < 0.001 0.470 NA
   High-dose 121 4.1 ± 2.8 106 2.9 ± 2.4 -1.2 ± 2.5 < 0.001 0.634 NA
Bloating/Distension
   Placebo 121 39.0 ± 28.0 118 30.7 ± 25.6   -8.3 ± 23.6 < 0.001 NA 0.669
   Low-dose 122 40.5 ± 29.9 110 31.0 ± 25.7   -9.4 ± 29.6 < 0.001 0.905 NA
   High-dose 122 37.1 ± 26.6 113 31.0 ± 27.3   -6.1 ± 25.8 0.002 0.535 NA
Satisfaction with bowel habits
   Placebo 121 57.4 ± 22.6 118 47.3 ± 24.2 -10.3 ± 21.4 < 0.001 NA 0.964
   Low-dose 124 59.4 ± 22.7 110 46.3 ± 19.8 -11.8 ± 22.4 < 0.001 0.701 NA
   High-dose 122 55.0 ± 19.7 113 46.4 ± 22.6   -8.3 ± 23.3 < 0.001 0.757 NA
Interference of IBS with quality of life
   Placebo 121 62.4 ± 17.0 118 48.6 ± 22.1 -13.9 ± 20.3 < 0.001 NA 0.210
   Low-dose 124 60.8 ± 16.9 110 50.1 ± 19.4   -9.8 ± 16.5 < 0.001 0.133 NA
   High-dose 122 59.8 ± 13.5 113 47.9 ± 16.5 -11.7 ± 13.6 < 0.001 0.509 NA
IBS: Irritable bowel syndrome.
Table 4  Change in pain score for volunteers with moderate or severe abdominal pain at baseline
Treatment n Baseline Week 12 Change from baseline Mean difference for combined active doses P  value
mean ± SD mean ± SD mean ± SD 95%CI
Placebo 29 51.1 (9.3) 30.3 (22.9) -20.8 (22.8)
Low-dose 36   53.6 (10.9) 24.4 (19.4) -29.4 (17.9) -9.5 (-18.8; -0.17) 0.046
High-dose 34   52.1 (10.7) 21.9 (20.6) -31.2 (21.9)
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IBS is associated with significant placebo effects, 
in part due to the subjective nature of the outcome 
measures (Shah and Pimentel, 2014). Our trial had 
an 8-wk run-in period during which volunteers did not 
consume any product (including placebo); thus, there 
was no pre-randomization selection for high placebo 
responders. The study products were administered 
daily, which should be beneficial for minimizing a 
placebo effect. However, the high frequency of contact 
by research nurses might have heightened the placebo 
response, although their attention and care were 
targeted originally toward evaluating safety adequately 
and ensuring high compliance with the protocol. 
Our principal challenge was the significant placebo 
effect, which was comparable with the efficacy of the 
active treatments. A decrease of > 50 in IBS-SSS 
indicates clinical improvement of symptoms[18]. In the 
present trial, the IBS-SSS decreased from 44.0 to 
50.8 in the 3 different treatment groups suggesting 
a borderline clinically significant effect. Similarly, IBS-
QoL scores corresponded to moderate symptom 
severity at baseline vs mild symptom severity by 
the end of treatment in all groups[21]. Also, with the 
AR questionnaire, the placebo was as effective as 
the active treatment. Volunteers had had difficulty 
comprehending whether the weekly AR question should 
be referenced to the base-line period, as intended, or 
to the previous calendar week. Thus some participants 
compared consecutive intervention weeks rather than 
treatment to baseline in the AR questionnaire.
HADS was applied to subgroup participants by 
psychological comorbidity which has previously been 
associated with characteristics of intestinal microbiota[29]. 
Statistically significant reductions in HADS were 
observed in the active treatment groups. However, 
these changes were small and likely of no clinical 
relevance; further, the prevalence of anxiety and 
depression was low, and for all treatment groups 
HADS averages throughout the study were at normal 
levels[22]. No subgroup analyses were implemented. 
Nevertheless, the changes in HADS indicate a target 
for future study in a more appropriate population.
Changes in stool consistency are not unexpected 
for an IBS population[30], and none of the treatments 
appeared to cause undesirable alterations in stool 
form. Defecation frequencies were close to normal 
limits, suggesting that diarrhea and constipation in IBS 
volunteers are subjective phenomena that are related 
to defecation events, rather than a result of hard stool 
and slow transit or loose stool and accelerated transit. 
Thus recruitment of all IBS symptom subtypes is 
justifiable.
Table 5  Change in irritable bowel syndrome-related quality of life and level of anxiety and depression (Hospital Anxiety and 
Depression Score)
Treatment Baseline Week 12 Change from 
baseline
Within-group 
comparison
Comparison with 
placebo
Comparison with low- 
and high-dose
n mean ± SD n mean ± SD mean ± SD P value P  value P  value
IBS-QoL
   Placebo 121   66.4 ± 17.5 118 73.2 ± 19.0     7.0 ± 12.3 < 0.001 NA 0.412
   Low-dose 124   63.9 ± 19.0 110 71.6 ± 19.3     7.4 ± 12.3 < 0.001 0.812 NA
   High-dose 122   68.2 ± 16.5 113 76.5 ± 15.8   8.5 ± 8.8 < 0.001 0.238 NA
HADS total score
   Placebo 119   9.2 ± 5.6 110 8.6 ± 6.6 -0.4 ± 4.3    0.302 NA 0.134
   Low-dose 122 10.1 ± 5.7 109 9.2 ± 6.0 -1.0 ± 4.4    0.034 0.435 NA
   High-dose 118   9.7 ± 5.5 109 8.2 ± 5.8 -1.5 ± 3.9 < 0.001 0.071 NA
HADS-Anxiety
   Placebo 121   5.9 ± 3.5 114 5.3 ± 3.6 -0.4 ± 2.6    0.036 NA 0.246
   Low-dose 122   6.1 ± 3.3 109 5.5 ± 3.1 -0.6 ± 2.7    0.011 0.726 NA
   High-dose 119   6.2 ± 3.3 109 5.0 ± 3.1 -1.0 ± 2.2 < 0.001 0.099 NA
HADS-Depression
   Placebo 119   3.4 ± 2.9 111 3.4 ± 3.6   0.0 ± 2.3    0.906 NA 0.162
   Low-dose 124   4.0 ± 3.0 109 3.7 ± 3.4 -0.3 ± 2.2    0.258 0.376 NA
   High-dose 119   3.5 ± 2.9 110 3.2 ± 3.1 -0.4 ± 2.4    0.041 0.125 NA
HADS: Hospital anxiety and depression score; IBS-QoL: Irritable bowel syndrome quality of life.
Table 6  Change in stool consistency from baseline according 
to Bristol stool scale1 n  (%)
n Change to optimal from 
constipation or diarrhea 
Change to constipation or 
diarrhea from optimal 
Placebo 131
   Week 4   18 (13.7)   15 (11.5)
   Week 12   21 (16.0)   18 (13.7)
   Washout   20 (15.3)   17 (13.0)
Low-dose 129
   Week 4   26 (20.2)   13 (10.1)
   Week 12   27 (20.9)   14 (10.9)
   Washout   14 (10.9) 12 (9.3)
High-dose 131
   Week 4   14 (10.7)   16 (12.2)
   Week 12   18 (13.7)   20 (15.3)
   Washout   14 (10.7)   18 (13.7)
Total 391 172 (44.0) 143 (36.6)
1Bristol stool scale types 1 and 2 were classified as constipation; 3, 4, and 5 
were classified as optimal stool consistency; and 6 and 7 were classified as 
diarrhea.
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Selecting volunteers from only 1 IBS symptom 
subgroup or setting a threshold for baseline symptom 
severity as applied by Sisson and colleagues[31] 
can reduce variation in the response to treatment. 
However, our objective was to recruit IBS volunteers 
as a representation of the general population[3], which 
would have been distorted by selecting subgroups 
or IBS patients with more severe symptoms. In 
addition, because the etiology of IBS is multifacto-
rial and, to a large extent, unknown and because 
symptom subgroups tend to vary over time in each 
volunteer[30], selecting between symptom subgroups 
is challenging. Moreover, excluding volunteers whom 
consume diarrhea medication, laxatives, and opiate- or 
morphine-containing pain medications was necessary, 
because these agents influence the outcome, but it 
also effectively excluded volunteers with severe IBS 
symptoms.
Another shortcoming in assessing the efficacy of 
bowel symptoms was the infrequent and retrospective 
evaluation of IBS symptoms[32]. The symptom 
questionnaires were administered 4 times in total and 
only twice during the 12-wk intervention period. More 
frequent assessments were initially considered to be 
a risk for noncompliance due to the laboriousness of 
answering so many questionnaires. Moreover, although 
the IBS-SSS questionnaire inquires about symptom 
severity over the past 10 d, the volunteers’ symptoms, 
everyday events, and mood when they complete 
the questionnaires are likely to bias the answers, 
resulting in potentially irrelevant variations in scores. 
Because volunteers were not severely symptomatic 
(mean IBS-SSS at baseline corresponded to moderate 
for all treatment groups), inquiring about symptom 
frequency instead of severity might have been more 
sensitive in measuring efficacy[33].
AEs were evenly distributed between groups. The 
slightly higher number of volunteer discontinuations 
due to AEs in the active high-dose group was not 
treatment-related. Digestive symptoms were the chief 
manifestation of the inclusion criteria of the study 
population; thus, GI discomfort, recorded as a possibly 
treatment-related AE, might have also been part of 
their normal symptomology. 
L. acidophilus NCFM can be consumed safely 
by adult IBS volunteers over a 3-mo period but is 
ineffective against IBS symptoms in general compared 
to placebo. However, L. acidophilus NCFM treatment 
alleviated abdominal pain in IBS volunteers with at 
least moderately severe visceral pain. More frequent 
- preferably daily - assessment of bowel symptoms 
with a user-friendly application is recommended for 
future trials in this area. Moreover, enquiring individual 
symptoms rather than a composite score sum may be 
more applicable. Among the recruited IBS participants 
with moderate symptom severity at baseline bowel 
movement frequency appeared normal regardless of 
stool consistency and anxiety and depression levels 
were not clinically notable.
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Background
Functional bowel symptoms are a common disturbance encountered transiently 
by most humans and in a chronic manner by many. Irritable bowel syndrome 
(IBS) is a functional bowel disorder with abdominal pain as its core symptom. 
In the present trial, Lactobacillus acidophilus NCFM, a probiotic bacterium 
that is known to enhance analgesic receptor expression in the gastrointestinal 
(GI) tract of rodents and humans, was evaluated for its ability to alleviate IBS 
symptoms.
Research frontiers
In probiotic research there is a great demand for high quality clinical trials to 
show potential health efficacy for well-defined probiotic strains. This applies 
to an array of health areas, including GI wellbeing. On the other hand, also 
mechanistic insight into the modes of action of probiotics is required to enlighten 
their efficacy.
Innovations and breakthrough
The present clinical trial was conducted with high quality applying an adequate 
population for statistical power and a well characterized probiotic strain with 
prior mechanistic efficacy data. A thorough set of participant-reported outcomes 
were evaluated on bowel symptoms, quality of life, psychological wellbeing and 
defecation habit and stool consistency. The participants complied well with the 
trial protocol allowing analysis of a comparatively large and complete dataset.
Applications
In the present trial the tested strain was not superior to placebo on IBS 
symptom alleviation in general. However, abdominal pain was relieved among 
participants with moderate to severe abdominal pain at baseline. The trial also 
gives insight into design and conduct of probiotic clinical trials on functional 
bowel disorders.
Peer-review 
This article describes a very well designed clinical trial on the effect of the 
probiotic strain L. acidophilus NCFM in two doses on symptoms in IBS patients. 
The trial design is of high-quality including the use of a well-defined strain, as 
well as an adequate number of participants and a long enough intervention 
period.
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